AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 27, 2024
The psychedelic drug psilocybin (as found in ‘magic’ mushrooms) has promising potential as a treatment for the eating disorder anorexia nervosa, according to new research that looked at its effects on an animal model of the condition.
Pharmaceutical Technology
MAY 27, 2024
South Korea has approved Eisai and Biogen’s LEQEMBI for adults with mild cognitive impairment due to mild Alzheimer's disease (AD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 27, 2024
The Advertising Standards Council of India (ASCI) has released its Annual Complaints Report, which offers a comprehensive analysis of advertisements that were considered objectionable in the fiscal year 2023–24. ASCI examined 10,093 complaints and investigated 8,299 advertisements.
Pharmaceutical Technology
MAY 27, 2024
Dr. Reddy's Laboratories' Russian subsidiary and Novartis Pharma signed a deal for the distribution of anti-diabetes products.
BioSpace
MAY 27, 2024
Flagging a risk of hypoglycemia, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Friday did not recommend the approval of Novo Nordisk’s once-weekly insulin icodec for type 1 diabetes.
Pharmaceutical Technology
MAY 27, 2024
Dimerix has entered into an agreement with Taiba to commercialise DMX-200 for treating FSGS kidney disease in the Middle East.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
MAY 27, 2024
Eli Lilly has annaounced a $5.3bn investment at its site in Lebanon, Indiana, US, to enhance API manufacturing capacity.
BioSpace
MAY 27, 2024
Approaches and targets for depression and other mental health illnesses have remained stagnant for decades. With several readouts for novel therapies on the horizon, that could be changing.
pharmaphorum
MAY 27, 2024
The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the result likely isn’t what they were hoping for.
BioSpace
MAY 27, 2024
The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
MAY 27, 2024
Sanofi should hear from the FDA in September about its filing for Sarclisa as a first-line therapy for multiple myeloma after a priority review
BioSpace
MAY 27, 2024
Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients with lung cancer, experts told BioSpace.
pharmaphorum
MAY 27, 2024
The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a confirmatory clinical trial
BioSpace
MAY 27, 2024
With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make regulatory submissions for the rare kidney diseases this year.
pharmaphorum
MAY 27, 2024
Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indiana, US, to $9 billion.
BioSpace
MAY 27, 2024
AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.
Cloudbyz
MAY 27, 2024
Although participation in clinical trials is essential to medical progress, a little-known fact is that they are not sufficiently diverse. Ultimately addressing these financial barriers is crucial for the optimal participation of all individuals in clinical trials. Diversity of Patients Racial and ethnic diversity are large barriers in clinical trials.
BioSpace
MAY 27, 2024
NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a late-stage confirmatory trial, showing no significant motor function improvements over placebo.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Patent Watch
MAY 27, 2024
ACULAR LS (ketorolac tromethamine) Abbvie Patent: 9,216,167 Expiration: May 28, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.
BioSpace
MAY 27, 2024
Following a series of clinical failures, optimism builds for the first disease-modifying treatment.
FDA Law Blog
MAY 27, 2024
Hyman, Phelps & McNamara, P.C. (HPM) proudly announces the return of Jennifer Newberger as a Director, further boosting its already robust medical device practice. Jennifer’s combination of experiences as in-house counsel for both large and start-up companies as well as outside counsel provides clients invaluable expertise and problem-solving skills.
BioSpace
MAY 27, 2024
Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the heels of J&J’s $850 million Proteologix bispecific antibody acquisition.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Commerce
MAY 27, 2024
The latest news for pharma industry insiders.
Drug Patent Watch
MAY 27, 2024
Annual Drug Patent Expirations for ACULAR+LS Acular Ls is a drug marketed by Abbvie and is included in one NDA. It is available from three suppliers.
Pharma Tutor
MAY 27, 2024
Neurocosmetics admin Mon, 05/27/2024 - 16:30 Vinay Kumar Singh. Head-Formulation Kumar Organic Products Research Centre Pvt. Ltd., Bengaluru Email : formulation_krc@kopresearchcentre.
Trialfacts
MAY 27, 2024
Contents Background Why Participate? Your Rights Who Can Participate? Study Location Research Centre: Monash Biomedical Imaging Location: 770 Blackburn Road, Clayton 3168 Lead Doctor: Professor Alex Fornito Ethics Committee: This study has been reviewed and approved by the Monash University Human Research Ethics Committee (Project #12692) Background People show differences in several characteristics, such as personality traits, that may make some people more prone to conditions such as anxiety a
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
JAMA Internal Medicine
MAY 27, 2024
This JAMA Internal Medicine Patient Page describes the advantages, risks, and safe use of cannabis edibles.
Pharmaceutical Commerce
MAY 27, 2024
The transaction serves as way to expand customers’ access to products and capabilities.
JAMA Internal Medicine
MAY 27, 2024
This Viewpoint examines artificial intelligence–enabled clinical services, existing payment structures, and the economics of artificial intelligence pricing.
Drug Patent Watch
MAY 27, 2024
This chart shows the pharmaceutical companies with the most patents in Lithuania.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
199 
Let's personalize your content